RapamycinFungusV1, Main, Exploration, bibRecord, 000349

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.

Identifieur interne : 000349 ( Main/Exploration ); précédent : 000348; suivant : 000350

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.

Auteurs : Hanzada Mohamed El Maghrabi [Égypte] ; Ahmed Yahia Elmowafy [Égypte] ; Ayman Fathi Refaie [Égypte] ; Mohammed Adel Elbasiony [Égypte] ; Gamal Elsayed Shiha [Égypte] ; Lionel Rostaing [France] ; Mohamed Adel Bakr [Égypte]

Source :

International urology and nephrology [ 1573-2584 ] ; 2019.

RBID : pubmed:31531807

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Complications postopératoires (traitement médicamenteux), Complications postopératoires (virologie), Femelle (MeSH), Génotype (MeSH), Hepacivirus (génétique), Humains (MeSH), Hépatite C chronique (traitement médicamenteux), Hépatite C chronique (virologie), Mâle (MeSH), Résultat thérapeutique (MeSH), Transplantation rénale (MeSH), Égypte (MeSH), Études prospectives (MeSH).
MESH :
- effets indésirables : Antiviraux.
- génétique : Hepacivirus.
- traitement médicamenteux : Complications postopératoires, Hépatite C chronique.
- usage thérapeutique : Antiviraux.
- virologie : Complications postopératoires, Hépatite C chronique.
- Adulte, Adulte d'âge moyen, Femelle, Génotype, Humains, Mâle, Résultat thérapeutique, Transplantation rénale, Égypte, Études prospectives.
Wicri :
- geographic : Égypte.

English descriptors

KwdEn :
- Adult (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Egypt (MeSH), Female (MeSH), Genotype (MeSH), Hepacivirus (genetics), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (virology), Humans (MeSH), Kidney Transplantation (MeSH), Male (MeSH), Middle Aged (MeSH), Postoperative Complications (drug therapy), Postoperative Complications (virology), Prospective Studies (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- geographic : Egypt.
- drug therapy : Hepatitis C, Chronic, Postoperative Complications.
- genetics : Hepacivirus.
- virology : Hepatitis C, Chronic, Postoperative Complications.
- Adult, Female, Genotype, Humans, Kidney Transplantation, Male, Middle Aged, Prospective Studies, Treatment Outcome.

Abstract

PURPOSE

Hepatitis C virus (HCV) infection in kidney transplant recipients (KTRs) is common and can impact on patient and graft survival rates. The efficacy and safety of direct-acting antivirals (DAAs) to treat genotype-4 HCV-infected KTRs have not been fully established.

METHODS

A prospective, single-arm, single-center study was conducted at Mansoura Urology/Nephrology Center (Mansoura University, Egypt). 114 HCV RNA(+) genotype 4 KTRs were enrolled in this study after a hepatology consultation and consented to start treatment with interferon-free DAAs. A sofosbuvir-based regimen was given to 109 recipients that had creatinine clearance (Crcl) of > 30 mL/min/1.73 m

RESULTS

The mean age of the cohort was 45.2 ± 11.2 years; most were male. The mean duration with a transplant was 14.2 ± 3.5 years, with different immunosuppressive regimens, mostly based on calcineurin inhibitors. A rapid virological response (RVR), i.e., clearance of viral load, was achieved in 100% at 4 weeks after starting treatment. All patients had a sustained virological response (SVR) at 12 and 24 weeks posttreatment, with one exception. During DAA therapy serum creatinine increased in 12 patients. In three, this was concomitant with elevated calcineurin inhibitor and sirolimus trough levels. Graft biopsies were performed in 8 of these 12 patients: these revealed an acute rejection in 4 cases (acute cellular rejection grade-1A: n = 2, and grade-1B: n = 2). The rejection episodes occurred at 4-6 weeks after starting treatment.

CONCLUSION

DAAs were highly efficacious and safely treated genotype-4 HCV-infected KTRs and had no significant adverse effects on graft function/survival.

DOI: 10.1007/s11255-019-02272-5
PubMed: 31531807

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000195
to stream Main, to step Curation: 000195

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.</title>
<author><name sortKey="Maghrabi, Hanzada Mohamed El" sort="Maghrabi, Hanzada Mohamed El" uniqKey="Maghrabi H" first="Hanzada Mohamed El" last="Maghrabi">Hanzada Mohamed El Maghrabi</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Nephrology Department, Port-Said University, Port Said, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Nephrology Department, Port-Said University, Port Said</wicri:regionArea>
<wicri:noRegion>Port Said</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elmowafy, Ahmed Yahia" sort="Elmowafy, Ahmed Yahia" uniqKey="Elmowafy A" first="Ahmed Yahia" last="Elmowafy">Ahmed Yahia Elmowafy</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Refaie, Ayman Fathi" sort="Refaie, Ayman Fathi" uniqKey="Refaie A" first="Ayman Fathi" last="Refaie">Ayman Fathi Refaie</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elbasiony, Mohammed Adel" sort="Elbasiony, Mohammed Adel" uniqKey="Elbasiony M" first="Mohammed Adel" last="Elbasiony">Mohammed Adel Elbasiony</name>
<affiliation wicri:level="1"><nlm:affiliation>Egyptian Liver research Institute and Hospital, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Egyptian Liver research Institute and Hospital, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Internal Medicine Department, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shiha, Gamal Elsayed" sort="Shiha, Gamal Elsayed" uniqKey="Shiha G" first="Gamal Elsayed" last="Shiha">Gamal Elsayed Shiha</name>
<affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Internal Medicine Department, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rostaing, Lionel" sort="Rostaing, Lionel" uniqKey="Rostaing L" first="Lionel" last="Rostaing">Lionel Rostaing</name>
<affiliation wicri:level="3"><nlm:affiliation>Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, CS 10217, 38043, Grenoble Cedex 09, France. lrostaing@chu-grenoble.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, CS 10217, 38043, Grenoble Cedex 09</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Grenoble</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bakr, Mohamed Adel" sort="Bakr, Mohamed Adel" uniqKey="Bakr M" first="Mohamed Adel" last="Bakr">Mohamed Adel Bakr</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31531807</idno>
<idno type="pmid">31531807</idno>
<idno type="doi">10.1007/s11255-019-02272-5</idno>
<idno type="wicri:Area/Main/Corpus">000195</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000195</idno>
<idno type="wicri:Area/Main/Curation">000195</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000195</idno>
<idno type="wicri:Area/Main/Exploration">000195</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.</title>
<author><name sortKey="Maghrabi, Hanzada Mohamed El" sort="Maghrabi, Hanzada Mohamed El" uniqKey="Maghrabi H" first="Hanzada Mohamed El" last="Maghrabi">Hanzada Mohamed El Maghrabi</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Nephrology Department, Port-Said University, Port Said, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Nephrology Department, Port-Said University, Port Said</wicri:regionArea>
<wicri:noRegion>Port Said</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elmowafy, Ahmed Yahia" sort="Elmowafy, Ahmed Yahia" uniqKey="Elmowafy A" first="Ahmed Yahia" last="Elmowafy">Ahmed Yahia Elmowafy</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Refaie, Ayman Fathi" sort="Refaie, Ayman Fathi" uniqKey="Refaie A" first="Ayman Fathi" last="Refaie">Ayman Fathi Refaie</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elbasiony, Mohammed Adel" sort="Elbasiony, Mohammed Adel" uniqKey="Elbasiony M" first="Mohammed Adel" last="Elbasiony">Mohammed Adel Elbasiony</name>
<affiliation wicri:level="1"><nlm:affiliation>Egyptian Liver research Institute and Hospital, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Egyptian Liver research Institute and Hospital, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Internal Medicine Department, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shiha, Gamal Elsayed" sort="Shiha, Gamal Elsayed" uniqKey="Shiha G" first="Gamal Elsayed" last="Shiha">Gamal Elsayed Shiha</name>
<affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Internal Medicine Department, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rostaing, Lionel" sort="Rostaing, Lionel" uniqKey="Rostaing L" first="Lionel" last="Rostaing">Lionel Rostaing</name>
<affiliation wicri:level="3"><nlm:affiliation>Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, CS 10217, 38043, Grenoble Cedex 09, France. lrostaing@chu-grenoble.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, CS 10217, 38043, Grenoble Cedex 09</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Grenoble</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bakr, Mohamed Adel" sort="Bakr, Mohamed Adel" uniqKey="Bakr M" first="Mohamed Adel" last="Bakr">Mohamed Adel Bakr</name>
<affiliation wicri:level="1"><nlm:affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Urology and Nephrology Center, Mansoura University, Mansoura</wicri:regionArea>
<wicri:noRegion>Mansoura</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International urology and nephrology</title>
<idno type="eISSN">1573-2584</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Egypt (MeSH)</term>
<term>Female (MeSH)</term>
<term>Genotype (MeSH)</term>
<term>Hepacivirus (genetics)</term>
<term>Hepatitis C, Chronic (drug therapy)</term>
<term>Hepatitis C, Chronic (virology)</term>
<term>Humans (MeSH)</term>
<term>Kidney Transplantation (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Postoperative Complications (drug therapy)</term>
<term>Postoperative Complications (virology)</term>
<term>Prospective Studies (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Complications postopératoires (traitement médicamenteux)</term>
<term>Complications postopératoires (virologie)</term>
<term>Femelle (MeSH)</term>
<term>Génotype (MeSH)</term>
<term>Hepacivirus (génétique)</term>
<term>Humains (MeSH)</term>
<term>Hépatite C chronique (traitement médicamenteux)</term>
<term>Hépatite C chronique (virologie)</term>
<term>Mâle (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Transplantation rénale (MeSH)</term>
<term>Égypte (MeSH)</term>
<term>Études prospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Egypt</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term>
<term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Complications postopératoires</term>
<term>Hépatite C chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Complications postopératoires</term>
<term>Hépatite C chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C, Chronic</term>
<term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Kidney Transplantation</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Génotype</term>
<term>Humains</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Transplantation rénale</term>
<term>Égypte</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Égypte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b>
</p>
<p>Hepatitis C virus (HCV) infection in kidney transplant recipients (KTRs) is common and can impact on patient and graft survival rates. The efficacy and safety of direct-acting antivirals (DAAs) to treat genotype-4 HCV-infected KTRs have not been fully established.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>A prospective, single-arm, single-center study was conducted at Mansoura Urology/Nephrology Center (Mansoura University, Egypt). 114 HCV RNA(+) genotype 4 KTRs were enrolled in this study after a hepatology consultation and consented to start treatment with interferon-free DAAs. A sofosbuvir-based regimen was given to 109 recipients that had creatinine clearance (Crcl) of > 30 mL/min/1.73 m</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The mean age of the cohort was 45.2 ± 11.2 years; most were male. The mean duration with a transplant was 14.2 ± 3.5 years, with different immunosuppressive regimens, mostly based on calcineurin inhibitors. A rapid virological response (RVR), i.e., clearance of viral load, was achieved in 100% at 4 weeks after starting treatment. All patients had a sustained virological response (SVR) at 12 and 24 weeks posttreatment, with one exception. During DAA therapy serum creatinine increased in 12 patients. In three, this was concomitant with elevated calcineurin inhibitor and sirolimus trough levels. Graft biopsies were performed in 8 of these 12 patients: these revealed an acute rejection in 4 cases (acute cellular rejection grade-1A: n = 2, and grade-1B: n = 2). The rejection episodes occurred at 4-6 weeks after starting treatment.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>DAAs were highly efficacious and safely treated genotype-4 HCV-infected KTRs and had no significant adverse effects on graft function/survival.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31531807</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2584</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>51</Volume>
<Issue>12</Issue>
<PubDate><Year>2019</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>International urology and nephrology</Title>
<ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.</ArticleTitle>
<Pagination><MedlinePgn>2295-2304</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-019-02272-5</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Hepatitis C virus (HCV) infection in kidney transplant recipients (KTRs) is common and can impact on patient and graft survival rates. The efficacy and safety of direct-acting antivirals (DAAs) to treat genotype-4 HCV-infected KTRs have not been fully established.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, single-arm, single-center study was conducted at Mansoura Urology/Nephrology Center (Mansoura University, Egypt). 114 HCV RNA(+) genotype 4 KTRs were enrolled in this study after a hepatology consultation and consented to start treatment with interferon-free DAAs. A sofosbuvir-based regimen was given to 109 recipients that had creatinine clearance (Crcl) of > 30 mL/min/1.73 m<sup>2</sup>
. Ritonavir-boosted paritaprevir/ombitasvir was prescribed to five recipients with Crcl < 30 mL/min/1.73 m<sup>2</sup>
.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of the cohort was 45.2 ± 11.2 years; most were male. The mean duration with a transplant was 14.2 ± 3.5 years, with different immunosuppressive regimens, mostly based on calcineurin inhibitors. A rapid virological response (RVR), i.e., clearance of viral load, was achieved in 100% at 4 weeks after starting treatment. All patients had a sustained virological response (SVR) at 12 and 24 weeks posttreatment, with one exception. During DAA therapy serum creatinine increased in 12 patients. In three, this was concomitant with elevated calcineurin inhibitor and sirolimus trough levels. Graft biopsies were performed in 8 of these 12 patients: these revealed an acute rejection in 4 cases (acute cellular rejection grade-1A: n = 2, and grade-1B: n = 2). The rejection episodes occurred at 4-6 weeks after starting treatment.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DAAs were highly efficacious and safely treated genotype-4 HCV-infected KTRs and had no significant adverse effects on graft function/survival.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maghrabi</LastName>
<ForeName>Hanzada Mohamed El</ForeName>
<Initials>HME</Initials>
<AffiliationInfo><Affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Nephrology Department, Port-Said University, Port Said, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Elmowafy</LastName>
<ForeName>Ahmed Yahia</ForeName>
<Initials>AY</Initials>
<AffiliationInfo><Affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Refaie</LastName>
<ForeName>Ayman Fathi</ForeName>
<Initials>AF</Initials>
<AffiliationInfo><Affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Elbasiony</LastName>
<ForeName>Mohammed Adel</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Egyptian Liver research Institute and Hospital, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shiha</LastName>
<ForeName>Gamal Elsayed</ForeName>
<Initials>GE</Initials>
<AffiliationInfo><Affiliation>Internal Medicine Department, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rostaing</LastName>
<ForeName>Lionel</ForeName>
<Initials>L</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-5130-7286</Identifier>
<AffiliationInfo><Affiliation>Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, CS 10217, 38043, Grenoble Cedex 09, France. lrostaing@chu-grenoble.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bakr</LastName>
<ForeName>Mohamed Adel</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>09</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int Urol Nephrol</MedlineTA>
<NlmUniqueID>0262521</NlmUniqueID>
<ISSNLinking>0301-1623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004534" MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Direct antiviral agents (DAA)</Keyword>
<Keyword MajorTopicYN="N">Drug interactions</Keyword>
<Keyword MajorTopicYN="N">HCV infection</Keyword>
<Keyword MajorTopicYN="N">Kidney transplantation</Keyword>
<Keyword MajorTopicYN="N">Sofosbuvir</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>05</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>08</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>9</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>9</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31531807</ArticleId>
<ArticleId IdType="doi">10.1007/s11255-019-02272-5</ArticleId>
<ArticleId IdType="pii">10.1007/s11255-019-02272-5</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2017 Jul;96(30):e7568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28746204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2015 May;15(5):1313-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25708713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplant Proc. 2009 Apr;41(3):880-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19376378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2016 May;16(5):1588-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26604182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2010 Dec 15;90(11):1165-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20861806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Int. 2009 Dec;22(12):1117-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19656350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2017 Jan;91(1):24-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28003083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepat Med. 2017 May 15;9:17-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28553150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Gastroenterol. 2014 May;109(5):628-35; quiz 636</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24732866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Exp Hepatol. 2017 Sep;7(3):165-171</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28970701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplant Proc. 2016 Nov;48(9):2938-2940</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27932111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1999 Mar 16;130(6):461-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10075613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Gastroenterol. 2016 Jan 28;22(4):1650-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26819530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24720702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27667367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2017 Jul;101(7):1704-1710</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28009781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23607594</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Int. 2016 Sep;29(9):999-1007</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27203857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Dial. 2005 Jan-Feb;18(1):52-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15663766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2014 May;85(5):1238-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24786879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2004 May;30(1):110-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15072764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2017 Feb;83(2):269-293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27530469</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int Suppl. 2008 Apr;(109):S1-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18382440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Gastroenterol. 2017 Mar;36(2):137-140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28345112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Int. 2017 Sep;30(9):865-873</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28332729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplant Proc. 2018 Apr;50(3):743-745</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29661427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2014 Nov 15;384(9956):1756-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25078309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2008 Aug;49(2):274-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18571272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2003 Jul;42(1):184-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12830471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24428467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2014 Oct;14(10):2206-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25091274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2007 May;39(1):54-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17409018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2016 Jul 14;11(7):e0158431</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27415632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Aug 18;436(7053):973-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16107838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2005 Dec 15;80(11):1636-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16371937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2016 May;16(5):1474-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26587971</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>Égypte</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Grenoble</li>
</settlement>
</list>
<tree><country name="Égypte"><noRegion><name sortKey="Maghrabi, Hanzada Mohamed El" sort="Maghrabi, Hanzada Mohamed El" uniqKey="Maghrabi H" first="Hanzada Mohamed El" last="Maghrabi">Hanzada Mohamed El Maghrabi</name>
</noRegion>
<name sortKey="Bakr, Mohamed Adel" sort="Bakr, Mohamed Adel" uniqKey="Bakr M" first="Mohamed Adel" last="Bakr">Mohamed Adel Bakr</name>
<name sortKey="Elbasiony, Mohammed Adel" sort="Elbasiony, Mohammed Adel" uniqKey="Elbasiony M" first="Mohammed Adel" last="Elbasiony">Mohammed Adel Elbasiony</name>
<name sortKey="Elbasiony, Mohammed Adel" sort="Elbasiony, Mohammed Adel" uniqKey="Elbasiony M" first="Mohammed Adel" last="Elbasiony">Mohammed Adel Elbasiony</name>
<name sortKey="Elmowafy, Ahmed Yahia" sort="Elmowafy, Ahmed Yahia" uniqKey="Elmowafy A" first="Ahmed Yahia" last="Elmowafy">Ahmed Yahia Elmowafy</name>
<name sortKey="Maghrabi, Hanzada Mohamed El" sort="Maghrabi, Hanzada Mohamed El" uniqKey="Maghrabi H" first="Hanzada Mohamed El" last="Maghrabi">Hanzada Mohamed El Maghrabi</name>
<name sortKey="Refaie, Ayman Fathi" sort="Refaie, Ayman Fathi" uniqKey="Refaie A" first="Ayman Fathi" last="Refaie">Ayman Fathi Refaie</name>
<name sortKey="Shiha, Gamal Elsayed" sort="Shiha, Gamal Elsayed" uniqKey="Shiha G" first="Gamal Elsayed" last="Shiha">Gamal Elsayed Shiha</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Rostaing, Lionel" sort="Rostaing, Lionel" uniqKey="Rostaing L" first="Lionel" last="Rostaing">Lionel Rostaing</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000349 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000349 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31531807
   |texte=   Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31531807" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki